# TABLE OF CONTENTS

**Volume 96, Number 18, May 4, 2021**

## In Focus
- **829** Spotlight on the May 4 Issue
- **830** This Week’s *Neurology* Podcast

### Editorials
- **831** SLC32A1: One More Gene Contributing to the Solution of the Genetic Generalized Epilepsies Mystery  
  R. Guerrini and C. Marini
- **833** A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis  
  R.J. Fox and R.J. Kryscio
- **835** Embracing the Unknown in the Diagnosis of Traumatic Encephalopathy Syndrome  
  L.-N. Hazrati and N. Schwab

### Articles: Short Format
Full articles at Neurology.org/N

- **837** Association of SLC32A1 Missense Variants With Genetic Epilepsy With Febrile Seizures Plus  
  *Editorial, p. 831*

- **838** Network-Related Changes in Neurotransmitters and Seizure Propagation During Rodent Epileptogenesis  
  *CME Course*

### Ahead of Print Articles and Editorials
NPub.org/aheadofprint

---

### Content Preview

- **839** Age-at-Onset and APOE-Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease  
  D.S. Smirnov, D. Galasko, A. Hiniker, S.D. Edland, and D.P. Salmon  
  *CME Course*

- **840** Dual Sensory Impairment and Cognitive Impairment in the Korean Longitudinal Elderly Cohort  

- **841** Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration  
  *Open Access Article, Class of Evidence*

- **842** Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial  
  M.W. Koch, K. Sage, S. Kaur, J. Kim, G. Cerchiaro, V.W. Yong, G.R. Cutter, and L.M. Metz  
  *Editorial, p. 833*, *Class of Evidence*

- **843** Randomized Study of Metoclopramide Plus Diphenhydramine for Acute Posttraumatic Headache  
  *Class of Evidence*

- **844** Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying a-Synuclein—Containing Extracellular Vesicles  
  *Class of Evidence*

---

*Copyright © 2021 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.*
Call for Voices: Lived Experiences

The Editors of the Neurology specialty site Equity, Diversity, & Inclusion encourage you to submit short first-person accounts (1,000 words or less) of experiences lived within the realm of equity, diversity, and inclusion (EDI) with the goal of informing and enlightening our community on these critical issues. Some topics to consider include, but are not limited to:

- Descriptions of personal experiences that shaped your views of EDI.
- Reflections on the intersection between personal identity and career.
- Discussions at the intersection of EDI and neurology patient care, research, education, advocacy, or policy.

Submit your contributions to journal@neurology.org and include “Voices Submission” in the subject line.
This information is current as of January 1, 2021

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://n.neurology.org/content/96/18.full">http://n.neurology.org/content/96/18.full</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a></td>
</tr>
</tbody>
</table>

*Neurology* © is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.